DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for cervical adenosarcoma — screening already-approved drugs against its 7-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCervical adenosarcoma maps to a 7-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for cervical adenosarcoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
platelet derived growth factor receptor alpha (PDGFRA) — PDGFRA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet dimethylaminodrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5GRN · 1.77 Å · ligand N-[2-(dimethylamino)ethyl]-N-[[4-[[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]carbamoyl]phenyl]methyl]pyridine-3-carboxamide (748). Experimental structure, not a prediction.
What the evidence adds up to
Cervical adenosarcoma is a biphasic neoplasm with a benign epithelial and a malignant stromal component. It usually originates in the uterine corpus, rarely protrudes through the cervical os, and is often misdiagnosed as a cervical polyp. One 2022 case report describes a cervical adenosarcoma that showed endophytic growth, which is rare for this location. The patient had no watery discharge or obvious genital bleeding; a single episode of faint brown discharge occurred six months before diagnosis, and the tumour measured 4 cm.
A separate 2022 case report describes a fertile woman who had eight recurrences of a cervical polypoidal mass over ten years. Wide local excision under hysteroscopy was performed because she wished to preserve her uterus. Surgical pathology and immunohistochemistry revealed cervical adenosarcoma, which had progressed from a recurrent cervical adenofibroma. A hysterectomy with ovarian conservation was recommended, with regular follow-up for evidence of recurrence. The authors note that differential diagnosis of cervical adenofibroma is difficult and that adenosarcoma should be ruled out in women with recurrent cervical polypoidal masses, requiring combined histological and immunohistochemical investigation.
No drug treatment, systemic therapy, or repurposing strategy is mentioned in any of the abstracts. There are no data on response rates, survival, or any pharmacological intervention. The evidence consists entirely of two single-patient case reports, one of which describes a tumour with an atypical growth pattern and minimal symptoms, and the other a progression from a benign to a malignant lesion over multiple recurrences.
What is missing is any clinical trial, any cohort study, any investigation of drug therapy, and any systematic approach to treatment. There is no information on patient stratification, no biomarker data, and no funding for research into medical management of this rare cervical tumour.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Medical Cases · 2022 · 1 citations · open access
Uterine Cervical Adenosarcoma Showing an Endophytic Growth Pattern
AbstractAdenosarcomas are biphasic neoplasms that usually originate in the uterine corpus and comprise a benign epithelial component and a malignant stromal component. Uterine adenosarcomas typically present with abnormal genital bleeding, an enlarged uterus, and a tumor that protrudes into the endometrial cavity. These tumors rarely protrude through the cervical os and are often misdiagnosed as cervical polyps. We present the case of a patient with cervical adenosarcoma with characteristics different from those reported in previous cases. This tumor showed endophytic growth, which is rare in cervical adenosarcomas. No watery discharge or obvious genital bleeding was noted. Although the tumor measured 4 cm, vaginal bleeding was noted only once at 6 months before diagnosis and was in the form of faint brown discharge.
World Journal of Clinical Cases · 2022 · 0 citations · open access
Recurrent cervical adenofibroma progressing to adenosarcoma: a rare case report
AbstractOBJECTIVES: Cervical adenofibroma is a rare form of mixed mesodermal tumor that can present as cervical polyps with a tendency for local recurrence and progression. Few cases progressing to adenosarcoma have previously been reported. We report a case of cervical adenofibroma progressing to adenosarcoma, and we seek to remind clinicians of the method and importance of the differential diagnosis of this disease. A fertile woman was admitted in our department for the eighth recurrence of a cervical polypoidal mass which for the past 10 years. Recurrence of cervical adenofibroma was confirmed by ultrasound and MRI. A wide local excision under hysteroscopy was performed due to her strong desire to preserve the uterus. Surgical pathology and immunohistochemical interpretation revealed cervical adenosarcoma. A hysterectomy with conservation of the ovaries was recommended, with regular follow-ups for evidence of disease recurrence. CONCLUSIONS: Differential diagnoses of cervical adenofibroma are hard to prove. Adenosarcoma should be ruled out, especially in women presenting with recurrent cervical polypoidal masses. A combined histological/immunohistochemical investigation is mandatory.
Mothering Ideologies in the News: A Discourse Analysis of the Contested Terrain of Contemporary U.S. Motherhood
AbstractAdenosarcomas are biphasic neoplasms that usually originate in the uterine corpus and comprise a benign epithelial component and a malignant stromal component. Uterine adenosarcomas typically present with abnormal genital bleeding, an enlarged uterus, and a tumor that protrudes into the endometrial cavity. These tumors rarely protrude through the cervical os and are often misdiagnosed as cervical polyps. We present the case of a patient with cervical adenosarcoma with characteristics different from those reported in previous cases. This tumor showed endophytic growth, which is rare in cervical adenosarcomas. No watery discharge or obvious genital bleeding was noted. Although the tumor measured 4 cm, vaginal bleeding was noted only once at 6 months before diagnosis and was in the form of faint brown discharge.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
